Reported 3 days ago
Novo Holdings has finalized a $16.5 billion acquisition of contract manufacturer Catalent to enhance the production of its weight-loss drug Wegovy. The deal grants Novo Nordisk control over three manufacturing facilities in Italy, Belgium, and the U.S. Despite previous opposition from consumer groups, the acquisition received approval from the FTC and European regulators. The demand for Wegovy, which mimics the GLP-1 hormone to manage blood sugar and appetite, is surging in a market projected to be worth $150 billion annually in the next decade.
Source: YAHOO